Navigation Links
First and Only Weaning Product Based on 100% Non-Allergenic Amino-Acids Specifically Designed for Children With Cows' Milk Protein Allergy and Multiple Food Protein Intolerance
Date:6/11/2009

LIVERPOOL, England, June 11 /PRNewswire/ -- Nutricia, the European market leader in advanced medical nutrition, announces the launch of Neocate Nutra, the first and only weaning product made from 100% non-allergenic amino acids. Neocate Nutra has been specifically developed for weaning infants and older children with cows' milk protein allergy (CMPA) and multiple food protein intolerance (MFPI). Unlike many weaning products, Neocate Nutra contains no hidden allergens and is designed to provide children with the key essential nutrients they need for development. With its unique format, Neocate Nutra is suitable for taking infants through the various stages of weaning and also for older children on very restricted diets who are looking for convenient and varied food options.

Neocate Nutra represents a groundbreaking advance in the management of CMPA, a condition which affects between 2 to 7.5% of infants worldwide.(1) With the launch of Neocate Nutra, parents of CMPA infants of a weaning age and above can, for the first time, choose with confidence a weaning product that is made from 100% non-allergenic amino acids, ruling out any possible allergic reactions caused by an exposure to any trace of cows' milk. Neocate Nutra contains key essential nutrients potentially missing from a dairy-free diet and contains a child's full dietary requirements of calcium and two thirds of their daily requirements for iron and vitamin D*. This helps to ensure valuable nutrition for healthy bones, growth and development throughout the weaning stage and beyond.

"The weaning stage can be nerve-wracking for parents of infants with cows' milk protein allergy as there is often a fear that they may react to other foods. Having a weaning product that is totally milk-free and can be used to provide infants with new tastes and textures means one less thing for parents to worry about." said Dr. Adam Fox, Consultant & Honorary Seni
'/>"/>

SOURCE Nutricia
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Mobile Massage Team to Sponsor and Exhibit at First Annual Working Wellness Expo
2. Cord Blood Registry Maintains Solid Growth in First Quarter 2009
3. PEAK Surgical Announces First Use of PEAK PlasmaBlade(TM) in Europe
4. First-degree relatives of patients with bicuspid aortic valve should be screened
5. ‘HairConfirm' Is First Drug Test of Its Kind to Report Low/Medium/High Usage; Now Available at Local Discount Drug Marts
6. First Brain Training Consumers Guide Debunks Ten Brain Health Myths and Reviews 21 Products
7. Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia
8. Streamline Health(R) Solutions Reports First Quarter Results
9. Nonin Medical, Inc. Announces the First Bluetooth(R) Continua(TM) Certified Product
10. Courage Center Is First in Midwest to Offer Innovative Treatment for Movement Disorders
11. Kidney Community Launches Health Care Campaign to Improve Survival Rates of First-Year Dialysis Patients in Iowa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
(Date:12/4/2009)Case Western Reserve University researchers, from the School of Medicine,s Department of Nutrition, discovered two new metabolic pathways by which products of lipid peroxidation and some drugs of abus
(Date:12/4/2009)Dental tourism is a phenomenon that was started by people that were looking for an alternative to the high price of dental work in the US, Canada, and other countries. In their search for lower priced
(Date:12/4/2009)Move a response to pressure from federal regulators to crack down on abuse of opioid medications , , FRIDAY, Dec. 4 (HealthDay News) -- The makers of 24 different prescription painkillers on F
(Date:12/4/2009)Research and surveillance urged for at-risk patient groups , , FRIDAY, Dec. 4 (HealthDay News) -- Some childhood cancers, particularly Ewing sarcomas and central nervous system tumors, carry t
Breaking Medicine News(10 mins):Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:Makers of Powerful Painkillers Present Safety Plans 2
...edical,Foundation has been awarded a three-year te...rvices as the result of a recent survey by the Ame...detailed, concerted effort our team made to ensure...tified radiologist at Sutter Regional Medical Foun...
... Researchers from EPFL and Caltech have made an i...earn to predict risk. The research, appearing in ... will shed light on why certain kinds of risk, not...eous evaluation of risk. , Planning entails maki...
...rs and sisters can be tough work, as any youngest ...ologist at the University of North Carolina at Cha...ou should reserve any underdog sympathies for the ...om, which holds that baby birds that are laid befo...
...mission tomography (PET) and computed tomography (...ve method to evaluate response to radiation therap...up treatments, a study by researchers at the Unive...ailable online. , The clinical study is the first...
...tiatives are featured, DETROIT, March 12 Physici... inside look at how groundbreaking partnerships,am...ld of Michigan are,saving lives, improving patient...ted,by hospitals, physicians and the Blues to trul...
... National Chronic Disease ...rim results show,that participants in the Diabetes... clinical and patient satisfaction indicators in t...lling diabetes, the chronic,disease that affects 2...
Other Medicine News:Health News:Sutter Regional Medical Foundation Receives ACR Accreditation 2Health News:To bet or not to bet: How the brain learns to estimate risk 2Health News:Early bird doesn't always get worm, UNC researcher finds 2Health News:USC researchers find benefit for lymphoma patients in combined PET-CT scanning 2Health News:Partnerships Report Highlights How Blue Cross Blue Shield of Michigan, Physicians and Hospitals Are Working to Save Lives, Improve Care, Reduce Costs 2Health News:Partnerships Report Highlights How Blue Cross Blue Shield of Michigan, Physicians and Hospitals Are Working to Save Lives, Improve Care, Reduce Costs 3Health News:Partnerships Report Highlights How Blue Cross Blue Shield of Michigan, Physicians and Hospitals Are Working to Save Lives, Improve Care, Reduce Costs 4Health News:Diabetes Ten City Challenge Collaborative Model Shows Improved Patient Health Across Key Clinical Indicators 2Health News:Diabetes Ten City Challenge Collaborative Model Shows Improved Patient Health Across Key Clinical Indicators 3Health News:Diabetes Ten City Challenge Collaborative Model Shows Improved Patient Health Across Key Clinical Indicators 4
(Date:12/4/2009)SAN DIEGO, Calif., Dec. 4 Suneva Medical, a privately-held aesthetic medical device company, today announced the appointment of Philip Ranker as Vice President and Chief Financial Officer. In this r
(Date:12/4/2009)TARRYTOWN, N.Y., Dec. 4 Bayer Diabetes Care today announced the three grand prize winners of Bayer,s "Express Your Simple Win Creativity Contest." Nick Jonas, of the Jonas Brothers, selected the winn
(Date:12/4/2009)RARITAN, N.J., Dec. 4 Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the comorbidities reported to occur
Breaking Medicine Technology:Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 2Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 3Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3Caltech scientists create robot surrogate for blind persons in testing visual prostheses 10414 1Caltech scientists create robot surrogate for blind persons in testing visual prostheses 10414 2Caltech scientists create robot surrogate for blind persons in testing visual prostheses 10414 3CDPHP Launches National Network and Three In One Plan and Expands Member Incentives 59754 1CDPHP Launches National Network and Three In One Plan and Expands Member Incentives 59754 2CDPHP Launches National Network and Three In One Plan and Expands Member Incentives 59754 3CDPHP Launches National Network and Three In One Plan and Expands Member Incentives 59754 4Drugs for Inflammatory Bowel Might Increase Cancer Risk 59751 1Drugs for Inflammatory Bowel Might Increase Cancer Risk 59751 2
...Pharmaceutical Company,Limited (Takeda) announced ...nter, Inc. submitted a New Drug Application (NDA) ...(FDA) for alogliptin (development code:,SYR-322), ...inhibitor under,investigation for the treatment of...Inc., alogliptin was designed to selectively inhib...
...ontinence Who Have Failed Alternative ...Jan. 3 Tengion, Inc., a clinical,stage regenerati...neo-organs and neo-vessels, announced today it is ... trial of its Neo-Bladder Augment derived from,a p...udy is being conducted,at five hospitals in 10 adu...
Other Medicine Technology:Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S. 2Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S. 3Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S. 4Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder 2Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder 3Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder 4
Broncho-Cath® Endobronchial Tube with CPAP System
...made of silicone rubber with a wire reinforced end... of silicone rubber, Silbronco is soft and less tr...the tube will not soften like PVC tubes, which mak...lbronco is also especially useful when a tumor lif...
Portex Pedia-Trake® Pediatric Emergency Cricothyrotomy Kit
Melker Emergency Cricothyrotomy Catheter Sets
Medicine Products: